TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis
- Status
- UNKNOWN
- Phase
- PHASE2
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.
- Status
- COMPLETED
- Phase
- PHASE3
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
- Status
- UNKNOWN
- Phase
- N/A
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
CRAFT: The NCT-PMO-1602 Phase II Trial
- Status
- COMPLETED
- Phase
- PHASE2
TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
- Status
- TERMINATED
- Phase
- PHASE2
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
MARGetuximab Or Trastuzumab (MARGOT)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2